A new drug called FG-2216 can stimulate production of the hormone erythropoietin in dialysis patients — possibly offering a new approach to treatment of kidney disease-related anemia, according to a new study.
A new drug called FG-2216 can stimulate production of the hormone erythropoietin in dialysis patients — possibly offering a new approach to treatment of kidney disease-related anemia, according to a new study.